Aditxt, Inc. (OTC:ADTX)
| Market Cap | 2.77M-100.0% |
| Revenue (ttm) | 14.34K-74.1% |
| Net Income | -51.95M-104.3% |
| EPS | -0.05-1269.9% |
| Shares Out | 997.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,001 |
| Open | 0.00 |
| Previous Close | 0.00 |
| Day's Range | 0.00 - 0.00 |
| 52-Week Range | 0.00 - 18232.78 |
| Beta | 0.93 |
| Analysts | Buy |
| Price Target | 1280.00(+46043065.47%) |
| Earnings Date | Dec 2, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About ADTX
Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques. The company's developments include AditxtScore, a platform designed to empower individuals by providing insights into their immune profiles for better management and informed awareness of immune system attacks or dysfunctions. Aditxt also pioneers Apoptotic DNA Immunotherapy, a nucleic acid-based solution that emulates the body's inherent mechanisms for developing self-tolerance to its own tissues. Additionally, Aditxt is actively researching and developing ADi products with diverse therapeutic applications, such as for organ transplant procedures (including skin grafting), various autoimmune conditions, and allergic reactions. The company holds licensing agreements with esteemed institutions like Loma Linda University and Leland Stanford Junior University. Established in 2017, this Richmond, Virginia-headquartered company was initially known as ADiTx Therapeutics, Inc. before rebranding to Aditxt, Inc. in July 2021.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ADTX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ADTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ADTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ADTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ADTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ADTX from public contracts
Source: USAspending.gov
ADTX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ADTX’s recent data — informational, not investment advice